Trials / Completed
CompletedNCT03850782
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 515 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimatoprost (SR) | Study Eye: Cycles 1 - 3 administrations through the PRN treatment period. Fellow Eye: Standard of care or Bimatoprost SR. |
Timeline
- Start date
- 2019-02-28
- Primary completion
- 2025-08-08
- Completion
- 2025-08-08
- First posted
- 2019-02-22
- Last updated
- 2025-08-19
Locations
108 sites across 16 countries: United States, Argentina, Australia, Bulgaria, Czechia, Denmark, Germany, Hungary, Ireland, Italy, New Zealand, Poland, Russia, South Africa, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03850782. Inclusion in this directory is not an endorsement.